FDA Approves LISRAYA, First Oral Drug For Adult Dermatomyositis
Priovant's once-daily pill beat placebo in the largest dermatomyositis trial ever run, cutting patients' reliance on chronic steroids.
- Brepocitinib scored 46.5 on the Total Improvement Score at week 52, versus 31.2 for placebo.
- 55% of drug patients hit moderate improvement with minimal or no steroids, versus 30% on placebo.
- Among heavier steroid users, 45% quit corticosteroids entirely, compared with 29% given placebo.
Why it matters: Until now, the only remedy was a steroid dose harsh enough to become its own disease.